- cafead   Feb 12, 2025 at 10:02: AM
via US-based biopharmaceutical company Spinogenix has published top line outcomes from a Phase II trial of SPG601 for treating Fragile X syndrome (FXS), a genetic disorder linked to autism and intellectual disability, in adult male patients.
article source
article source